Melanoma: a model for testing new agents in combination therapies.

J Transl Med · 2010 · PMC2873374 · PMID 20406483

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

None the less, a phase 3 trial combining IL-2 with a single melanoma antigen epitope has demonstrated a significant improvement in overall response rate, progression free survival, and a strong trend in improvement of overall survival compared to treatment with IL-2 alone [ 63 ].

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.